PDCD1 and neoplasm: Therefore, immune checkpoint blockade (ICB) targeting the PD-1-PD-L1 axis has emerged as a strategy for overcoming T cell exhaustion and enhancing anti-tumour immunity with tremendous clinical success [12, 13].